Oruka Therapeutics, Inc. (ORKA) Stock Research
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Latest price: 84.52 · Sector: Healthcare
Recent Insider Transactions
| Insider | Type | Date | Value |
|---|---|---|---|
| Klein Lawrence Otto | sell | 2026-10-01 | 718754.98 |
| Klein Lawrence Otto | sell | 2026-10-01 | 16956 |
| Klein Lawrence Otto | sell | 2026-10-01 | 1354882.28 |
| Quinlan Paul T | sell | 2026-09-21 | 254195.77 |
| Agarwal Arjun | sell | 2026-09-21 | 51034.75 |
| Quinlan Paul T | sell | 2026-09-21 | 267869.81 |
| Quinlan Paul T | sell | 2026-09-21 | 56760 |
| Quinlan Paul T | sell | 2026-09-21 | 357591.89 |
| Goncalves Joana | sell | 2026-09-15 | 90637.37 |
| Goncalves Joana | sell | 2026-09-15 | 9421.72 |